Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05438563 · ClinicalTrials.gov registry record · NA

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

A NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT05438563 is a NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05438563, a NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultrasound device guided by MRI imaging to deliver high-energy sound waves, producing very high temperature to ablate (destroy) tumor cells in a targeted manner. The MRI-guided TULSA procedure may help patients avoid surgery and help improve prostate cancer patients' quality of life.

Conditions Studied

Prostate Carcinoma Stage II Prostate Cancer AJCC v8 Stage I Prostate Cancer AJCC v8

Interventions

  • PROCEDURE Biopsy
  • OTHER Questionnaire Administration
  • PROCEDURE Cystoscopy
  • PROCEDURE MRI-Guided Transurethral Ultrasound Ablation
  • PROCEDURE Digital Rectal Examination

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-04-06
Est. Completion 2027-03-07
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05438563

The ClinicalTrials.gov registry entry for NCT05438563 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biopsy is the first listed.

NCT05438563 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05438563 about?

NCT05438563 is a clinical study titled "MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer". This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultras...

What is the current status of trial NCT05438563?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-04-06. Estimated completion is 2027-03-07.

What conditions does trial NCT05438563 study?

This clinical trial studies the following conditions: Prostate Carcinoma, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8.

What interventions are being tested in trial NCT05438563?

The interventions under investigation include: Biopsy (PROCEDURE), Questionnaire Administration (OTHER), Cystoscopy (PROCEDURE), MRI-Guided Transurethral Ultrasound Ablation (PROCEDURE), Digital Rectal Examination (PROCEDURE).

Who is sponsoring clinical trial NCT05438563?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05438563 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Carcinoma

All registered trials for this condition

Stage II Prostate Cancer AJCC v8

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.